questionText: To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the potential impact of NICE's decision to restrict secondary breast cancer patient's access to Enhertu on the grounds of patient wellbeing.
answerText: The National Institute for Health and Care Excellence (NICE) makes independent, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded for eligible patients based on an evalua...
heading: Trastuzumab Deruxtecan